Marktanalyse - Human Insulin Market in China 2011-2015

TechNavio's analysts forecast the Human Insulin market in China to grow at a CAGR of 19.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the diabetic population in China. The Human Insulin market in China has also been witnessing increased number of corporate agreements. However, the high cost of human insulin could pose a challenge to the growth of this market.

TechNavio's report, the Human Insulin Market in China 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on China; it also covers the Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, and Tonghua Dongbao Pharmaceutical Co. Ltd. The report also includes other vendors such as Abbott Laboratories Inc., Bayer Healthcare AG, Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., Pfizer Inc., and Zhuhai United Laboratories Inc.

Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
 
You can request one free hour of analyst time when you purchase this report. Details provided within the report.


Press Release:

TechNavio Announces the Publication of its Report - Human Insulin Market in China 2011-2015

TechNavio today launched its report Human Insulin Market in China 2011-2015 based on an in-depth study focusing exclusively on China. The report aims to aid decision makers' understanding of the present and future landscape of the market.



Commenting on the report, an analyst from TechNavio's Healthcare team said; ''The Human Insulin market in China has recently been witnessing a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. In addition to the corporate agreements, the Human Insulin market in China is experiencing significant focus on innovation and product development.''



According to the report, one of the major growth factors driving the Human Insulin market in China is the significant increase in the number of patients suffering from diabetes and diabetes-related diseases in the country.



Further, the report also discusses that one of the major challenges is the high cost of the human insulin that is provided mainly by the leading vendors in China.



The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.



TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies.

01. Executive Summary

02. Introduction

03. Market Coverage

Market Overview

Key Offerings

04. Market Landscape

04.1 Insulin Market in China

04.2 Human Insulin Market in China

Market Size

Market Forecast

Five Forces Analysis

05. Rate of Incidence and Prevalence

Diabetes

06. Vendor Landscape

Vendor Strategies

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis

13.1 Novo Nordisk A/S

Business Overview

SWOT Analysis

13.2 Sanofi SA

Business Overview

SWOT Analysis

13.3 Eli Lilly and Co.

Business Overview

SWOT Analysis

13.4 Tonghua Dongbao Pharmaceutical Co. Ltd.

Business Overview

SWOT Analysis

14. Other Reports in this Series



List of Exhibits:

Exhibit 1: Insulin Market in China 2011-2015 (US$ million)

Exhibit 2: Insulin Market in China by Product Segmentation

Exhibit 3: Insulin Market in China by Category Segmentation 2011

Exhibit 4: Insulin Market in China 2011-2015 by Revenue Segmentation (US$ million)

Exhibit 5: Insulin Market in China 2011-2015 by Segmentation (percentage)

Exhibit 6: Human Insulin Market in China 2011-2015 (US$ million)

Exhibit 7: Human Insulin Market in China by Vendor Segmentation 2011

• Diabetes – Pipeline Review, H1 2013
• Diabetic Foot Ulcers – Pipeline Review, H1 2013
• Diabetic Nephropathy – Pipeline Review, H1 2013
• Diabetic Neuropathy – Pipeline Review, H1 2013
• Type 2 Diabetes – Pipeline Review, H1 2013
• Global Insulin Antidiabetics Market 2012-2016
• Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
• Adult Mouth Care in Romania
• Global Diabetes Drugs Market 2011-2015
• Argentina Diabetes Care Devices Market Outlook to 2018
• Asia-Pacific Diabetes Care Devices Market Outlook to 2018
• Australia Diabetes Care Devices Market Outlook to 2018
• Austria Diabetes Care Devices Market Outlook to 2018
• Belgium Diabetes Care Devices Market Outlook to 2018
• Brazil Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Canada Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Chile Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2018
• China Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Czech Republic Diabetes Care Devices Market Outlook to 2018
• Denmark Diabetes Care Devices Market Outlook to 2018